Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07021040 · ClinicalTrials.gov registry record · NA
Olfactory Biopsies
A NA study of Alzheimer Disease and Smell Loss, sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT07021040: Recruiting NA study of Alzheimer Disease and Smell Loss, sponsored by Duke University.
NCT07021040 is a NA study of Alzheimer Disease and Smell Loss that is actively recruiting participants, run by Duke University. The registered enrollment target is 125 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07021040, a NA study of Alzheimer Disease and Smell Loss, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study aims to investigate the function of the olfactory lining in the nasal cavity and its potential alterations in both healthy and diseased conditions. The olfactory lining is involved in the sense of smell. The purpose of this study is to collect tissue from the nasal cavity.
Primary Outcome
Using single cell RNA-sequencing, olfactory epithelial cell populations will be analyzed for changes in coherent gene expression programs from subjects in different environmental conditions.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST olfactory testing
- OTHER Odor stimulation
- PROCEDURE Olfactory biopsy
Study Locations (1)
North Carolina
- Duke University Health Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-01-06 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT07021040 shows while recruiting
NCT07021040 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 3 interventions - of which olfactory testing is the first listed.
NCT07021040 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT07021040 about?
NCT07021040 is a clinical study titled "Olfactory Biopsies". This research study aims to investigate the function of the olfactory lining in the nasal cavity and its potential alterations in both healthy and diseased conditions. The olfactory lining is involved in the sense of smell. The purpose of this study is to collect tissue from the nasal cavity.
What is the current status of trial NCT07021040?
This trial is currently recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2025-01-06. Estimated completion is 2028-12-31.
What conditions does trial NCT07021040 study?
This clinical trial studies the following conditions: Alzheimer Disease, Smell Loss, Smell Dysfunction.
What interventions are being tested in trial NCT07021040?
The interventions under investigation include: olfactory testing (DIAGNOSTIC_TEST), Odor stimulation (OTHER), Olfactory biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT07021040?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07021040 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07021040's enrollment target sits among peer trials
125 137th of 306 higher than 169 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI